3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery

NCT00288093 PHASE1 COMPLETED

This phase I trial is studying the side effects and best dose of 3-AP when given together with radiation therapy in treating patients with stage III pancreatic cancer that cannot be removed by surgery. 3-AP may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. 3-AP may make tumor cells more sensitive to radiation therapy. Giving 3-AP together with radiation therapy may kill more tumor cells.

Details

Lead sponsor	National Cancer Institute (NCI)
Phase	PHASE1
Status	COMPLETED
Enrolment	30
Start date	Wed Dec 20 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 28 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Pancreatic Adenocarcinoma
• Stage III Pancreatic Cancer AJCC v6 and v7

Interventions

• 3-Dimensional Conformal Radiation Therapy
• Triapine

Countries

United States